NCT05048238View on ClinicalTrials.gov

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

February 15, 2024

Study Completion Date

February 29, 2024

Conditions
Cutaneous Lupus
Interventions
DRUG

Tofacitinib

10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis

Trial Locations (2)

48109

University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor

01605

University of Massachusetts Medical School, Worcester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH